AAREYDRUGS vs CIPLA: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Cipla Ltd

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows faster revenue growth, while Cipla Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Cipla Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 5 of 13 scored metrics and CIPLA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹221 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹1.47
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0%
Revenue Growth (TTM YoY)
AAREYDRUGS has faster revenue growth
19.8% vs -2.1%
EPS Growth (TTM YoY)
AAREYDRUGS has faster EPS growth
-41.05% vs -54.6%
Qtr Sales Growth
AAREYDRUGS has stronger quarterly sales growth
0% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSCIPLA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSCIPLA
Live Price₹90.51₹1,412.3
Day Change-4.92%-1.41%
Volume2.2 L12.96 L
52-Week High₹96₹1,673
52-Week Low₹50.31₹1,165.7
Distance from 52W High-5.72%-15.58%

Valuation

MetricAAREYDRUGSCIPLA
Market Cap₹221 Cr₹1.14 L Cr
P/E Ratio55.36x29.83x
P/B Ratio1.46x3.36x
EPS₹1.47₹48.01
Book Value₹48.67₹426.25
Dividend Yield0%0.9%

Growth

MetricAAREYDRUGSCIPLA
Revenue Growth (TTM YoY)19.8%-2.1%
EPS Growth (TTM YoY)-41.05%-54.6%
Qtr Sales Growth0%-2.8%
Qtr Profit Growth0%-54.6%

Profitability & Leverage

MetricAAREYDRUGSCIPLA
ROE2.64%11.6%
ROCE6%15.5%
Net Margin0.84%13.96%
Operating Margin2.21%20.9%
Debt to Equity0.33x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSCIPLA
Promoter Holding37.71% 1.35 pp9.17%
FII Holding4.18% 0.32 pp22.56% 1.37 pp
DII Holding1.62% 1.62 pp31.97% 1.25 pp
Public Holding56.49% 0.6 pp16.25% 0.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Cipla Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.